Nektar Therapeutics
NKTR· Nasdaq
Released Aug 4, 2022, after the close
10-Q filed Aug 5, 2022, 36 days after period end · 0000906709-22-000014
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $21.59M | $28.33M | $48.85M | $23.32M |
| Net Income | -$159.07M | -$125.52M | -$80.00M | -$110.29M |
| EPS Diluted |
Nektar Therapeutics · CIK 906709 · Engraved from SEC EDGAR
| -$0.85 |
| -$0.69 |
| -$0.45 |
| -$0.63 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.